Literature DB >> 22039581

Severe hepatocellular disease in mice lacking one or both CaaX prenyltransferases.

Shao H Yang1, Sandy Y Chang, Yiping Tu, Gregory W Lawson, Martin O Bergo, Loren G Fong, Stephen G Young.   

Abstract

Protein farnesyltransferase (FTase) and protein geranylgeranyltransferase-I (GGTase-I) add 15- or 20-carbon lipids, respectively, to proteins that terminate with a CaaX motif. These posttranslational modifications of proteins with lipids promote protein interactions with membrane surfaces in cells, but the in vivo importance of the CaaX prenyltransferases and the protein lipidation reactions they catalyze remain incompletely defined. One study concluded that a deficiency of FTase was inconsequential in adult mice and led to little or no tissue pathology. To assess the physiologic importance of the CaaX prenyltransferases, we used conditional knockout alleles and an albumin-Cre transgene to produce mice lacking FTase, GGTase-I, or both enzymes in hepatocytes. The hepatocyte-specific FTase knockout mice survived but exhibited hepatocellular disease and elevated transaminases. Mice lacking GGTase-I not only had elevated transaminases but also had dilated bile cannaliculi, hyperbilirubinemia, hepatosplenomegaly, and reduced survival. Of note, GGTase-I-deficient hepatocytes had a rounded shape and markedly reduced numbers of actin stress fibers. Hepatocyte-specific FTase/GGTase-I double-knockout mice closely resembled mice lacking GGTase-I alone, but the disease was slightly more severe. Our studies refute the notion that FTase is dispensable and demonstrate that GGTase-I is crucial for the vitality of hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22039581      PMCID: PMC3243483          DOI: 10.1194/jlr.M021220

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  42 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

3.  Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.

Authors:  R B Lobell; C A Omer; M T Abrams; H G Bhimnathwala; M J Brucker; C A Buser; J P Davide; S J deSolms; C J Dinsmore; M S Ellis-Hutchings; A M Kral; D Liu; W C Lumma; S V Machotka; E Rands; T M Williams; S L Graham; G D Hartman; A I Oliff; D C Heimbrook; N E Kohl
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 4.  Rho GTPases and the actin cytoskeleton.

Authors:  A Hall
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

Review 5.  Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design.

Authors:  E C Lerner; A D Hamilton; S M Sebti
Journal:  Anticancer Drug Des       Date:  1997-06

Review 6.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic.

Authors:  J B Gibbs; A Oliff; N E Kohl
Journal:  Cell       Date:  1994-04-22       Impact factor: 41.582

Review 7.  Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.

Authors:  S M Sebti; A D Hamilton
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

8.  Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice.

Authors:  Loren G Fong; Jennifer K Ng; Margarita Meta; Nathan Coté; Shao H Yang; Colin L Stewart; Terry Sullivan; Andrew Burghardt; Sharmila Majumdar; Karen Reue; Martin O Bergo; Stephen G Young
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

Review 9.  Prelamin A farnesylation and progeroid syndromes.

Authors:  Stephen G Young; Margarita Meta; Shao H Yang; Loren G Fong
Journal:  J Biol Chem       Date:  2006-11-07       Impact factor: 5.157

Review 10.  Protein prenylation: molecular mechanisms and functional consequences.

Authors:  F L Zhang; P J Casey
Journal:  Annu Rev Biochem       Date:  1996       Impact factor: 23.643

View more
  9 in total

1.  Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24.

Authors:  Sandy Y Chang; Sarah E Hudon-Miller; Shao H Yang; Hea-Jin Jung; John M Lee; Emily Farber; Thangaiah Subramanian; Douglas A Andres; H Peter Spielmann; Christine A Hrycyna; Stephen G Young; Loren G Fong
Journal:  J Lipid Res       Date:  2012-03-23       Impact factor: 5.922

2.  Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors.

Authors:  Stephen A Adam; Veronika Butin-Israeli; Megan M Cleland; Takeshi Shimi; Robert D Goldman
Journal:  Nucleus       Date:  2013-03-01       Impact factor: 4.197

3.  Targeting GGTase-I activates RHOA, increases macrophage reverse cholesterol transport, and reduces atherosclerosis in mice.

Authors:  Omar M Khan; Murali K Akula; Kristina Skålen; Christin Karlsson; Marcus Ståhlman; Stephen G Young; Jan Borén; Martin O Bergo
Journal:  Circulation       Date:  2013-01-18       Impact factor: 29.690

Review 4.  Targeting protein prenylation in progeria.

Authors:  Stephen G Young; Shao H Yang; Brandon S J Davies; Hea-Jin Jung; Loren G Fong
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

5.  Depletion of essential isoprenoids and ER stress induction following acute liver-specific deletion of HMG-CoA reductase.

Authors:  Marco De Giorgi; Kelsey E Jarrett; Jason C Burton; Alexandria M Doerfler; Ayrea Hurley; Ang Li; Rachel H Hsu; Mia Furgurson; Kalyani R Patel; Jun Han; Christoph H Borchers; William R Lagor
Journal:  J Lipid Res       Date:  2020-10-27       Impact factor: 5.922

6.  In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.

Authors:  Staci L Haney; Michelle L Varney; Yashpal Chhonker; Geoffrey Talmon; Lynette M Smith; Daryl J Murry; Sarah A Holstein
Journal:  Pharmacol Res       Date:  2021-03-03       Impact factor: 7.658

7.  Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24.

Authors:  Shahid Mehmood; Julien Marcoux; Joseph Gault; Andrew Quigley; Susan Michaelis; Stephen G Young; Elisabeth P Carpenter; Carol V Robinson
Journal:  Nat Chem       Date:  2016-08-15       Impact factor: 24.427

8.  Inhibition of farnesyl pyrophosphate synthase improves pressure overload induced chronic cardiac remodeling.

Authors:  Chen-Ze Zhao; Xu-Ming Zhao; Jian Yang; Yun Mou; Bin Chen; Huan-Dong Wu; Dong-Pu Dai; Jie Ding; Shen-Jiang Hu
Journal:  Sci Rep       Date:  2016-12-23       Impact factor: 4.379

9.  Mevalonate metabolism-dependent protein geranylgeranylation regulates thymocyte egress.

Authors:  Xingrong Du; Hu Zeng; Shaofeng Liu; Cliff Guy; Yogesh Dhungana; Geoffrey Neale; Martin O Bergo; Hongbo Chi
Journal:  J Exp Med       Date:  2020-02-03       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.